These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 19854938)

  • 1. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.
    Stein CA; Hansen JB; Lai J; Wu S; Voskresenskiy A; Høg A; Worm J; Hedtjärn M; Souleimanian N; Miller P; Soifer HS; Castanotto D; Benimetskaya L; Ørum H; Koch T
    Nucleic Acids Res; 2010 Jan; 38(1):e3. PubMed ID: 19854938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of gene expression by gymnotic delivery of antisense oligonucleotides.
    Soifer HS; Koch T; Lai J; Hansen B; Hoeg A; Oerum H; Stein CA
    Methods Mol Biol; 2012; 815():333-46. PubMed ID: 22131003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents.
    Torres AG; Threlfall RN; Gait MJ
    Artif DNA PNA XNA; 2011; 2(3):71-8. PubMed ID: 22567190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.
    Castanotto D; Lin M; Kowolik C; Koch T; Hansen BR; Oerum H; Stein CA
    Mol Ther; 2016 Jun; 24(6):1117-1125. PubMed ID: 26961407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection.
    Zhang Y; Qu Z; Kim S; Shi V; Liao B; Kraft P; Bandaru R; Wu Y; Greenberger LM; Horak ID
    Gene Ther; 2011 Apr; 18(4):326-33. PubMed ID: 21179173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro.
    González-Barriga A; Nillessen B; Kranzen J; van Kessel IDG; Croes HJE; Aguilera B; de Visser PC; Datson NA; Mulders SAM; van Deutekom JCT; Wieringa B; Wansink DG
    Nucleic Acid Ther; 2017 Jun; 27(3):144-158. PubMed ID: 28375678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression.
    Buntz A; Killian T; Schmid D; Seul H; Brinkmann U; Ravn J; Lindholm M; Knoetgen H; Haucke V; Mundigl O
    Nucleic Acids Res; 2019 Jan; 47(2):953-969. PubMed ID: 30462278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.
    Moschos SA; Frick M; Taylor B; Turnpenny P; Graves H; Spink KG; Brady K; Lamb D; Collins D; Rockel TD; Weber M; Lazari O; Perez-Tosar L; Fancy SA; Lapthorn C; Green MX; Evans S; Selby M; Jones G; Jones L; Kearney S; Mechiche H; Gikunju D; Subramanian R; Uhlmann E; Jurk M; Vollmer J; Ciaramella G; Yeadon M
    Mol Ther; 2011 Dec; 19(12):2163-8. PubMed ID: 21971426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
    Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
    Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical modification study of antisense gapmers.
    Stanton R; Sciabola S; Salatto C; Weng Y; Moshinsky D; Little J; Walters E; Kreeger J; DiMattia D; Chen T; Clark T; Liu M; Qian J; Roy M; Dullea R
    Nucleic Acid Ther; 2012 Oct; 22(5):344-59. PubMed ID: 22852836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Silencing of lncRNAs Using LNA GapmeRs.
    Taiana E; Favasuli V; Ronchetti D; Morelli E; Tassone P; Viglietto G; Munshi NC; Neri A; Amodio N
    Methods Mol Biol; 2021; 2348():157-166. PubMed ID: 34160805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS; Wengel J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2-A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling.
    Kuespert S; Heydn R; Peters S; Wirkert E; Meyer AL; Siebörger M; Johannesen S; Aigner L; Bogdahn U; Bruun TH
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense 2'-Deoxy, 2'-Fluroarabino Nucleic Acids (2'F-ANAs) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids.
    Souleimanian N; Deleavey GF; Soifer H; Wang S; Tiemann K; Damha MJ; Stein CA
    Mol Ther Nucleic Acids; 2012 Sep; 1(10):e43. PubMed ID: 23344235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells.
    Castanotto D; Lin M; Kowolik C; Wang L; Ren XQ; Soifer HS; Koch T; Hansen BR; Oerum H; Armstrong B; Wang Z; Bauer P; Rossi J; Stein CA
    Nucleic Acids Res; 2015 Oct; 43(19):9350-61. PubMed ID: 26433227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
    Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
    PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
    Uemura Y; Hagiwara K; Kobayashi K
    PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.
    Giles RV; Spiller DG; Grzybowski J; Clark RE; Nicklin P; Tidd DM
    Nucleic Acids Res; 1998 Apr; 26(7):1567-75. PubMed ID: 9512525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of bovine milk extracellular vesicles for the delivery of locked nucleic acid antisense oligonucleotides.
    Grossen P; Portmann M; Koller E; Duschmalé M; Minz T; Sewing S; Pandya NJ; van Geijtenbeek SK; Ducret A; Kusznir EA; Huber S; Berrera M; Lauer ME; Ringler P; Nordbo B; Jensen ML; Sladojevich F; Jagasia R; Alex R; Gamboni R; Keller M
    Eur J Pharm Biopharm; 2021 Jan; 158():198-210. PubMed ID: 33248268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.
    Buck AC; Shen C; Schirrmeister H; Schmid-Kotsas A; Munzert G; Guhlmann A; Mehrke G; Klug N; Gross HJ; Bachem M; Reske SN
    Cancer Biother Radiopharm; 2002 Jun; 17(3):281-9. PubMed ID: 12136520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.